MediPoint: Rheumatoid Arthritis Testing - Global Analysis and Market Forecasts

MediPoint: Rheumatoid Arthritis Testing - Global Analysis and Market Forecasts

Summary

Rheumatoid Arthritis (RA) is the commonest autoimmune disease in humans. The disease is prevalent in all ethnic groups, affecting approximately 1.0% of the world population. Presently there is a huge presence of unmet patient needs for both the treatment and diagnosis.

Focus for the treatment paradigm has now shifted towards the early detection and diagnosis of the disease, which will allow physicians to begin aggressive treatment of the condition, minimizing the associated complications and tissue damage.

Global sales of $347m in 2016 and estimated growth rate of 2% during the forecast period; the emerging markets: Brazil, Canada, China and Mexico are expected to show the fastest growth.

Key market drivers -

  • Increasing prevalence of autoimmune diseases globally including RA
  • Emerging biomarkers and advancement in technology for the early diagnosis of RA
  • Increasing adoption of anti-cyclic citrullinated peptide (anti-CCP) antibody test
  • Rising demand for lab automation
Key market barriers -
  • Limited sensitivity of existing RA diagnostic tests
  • Healthcare cost-cutting and reduced reimbursement in major markets
Highlights

Key Questions Answered
  • What is the current and future RA testing market outlook in the developed and emerging markets? What trends are affecting the global market?
  • What is the competitive landscape and who are major players in the RA testing space?
  • What are the key, high growth markets that IVD manufacturers should expand into? Which market segments are growing the fastest?
  • What are the unmet needs with the RA tests currently on the market? How will emerging technologies such as POC assays fulfil these unmet needs?
  • What are the key products and pipelines in the RA testing market?
  • What are the challenges and barriers that have hindered widespread adoption of RA tests in different regions?
Scope
  • Competitive assessment: Currently marketed RA diagnostic products and evolving competitive landscape
  • In-depth analysis of unmet needs and adoption trends of different RA diagnostic tests
  • Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
  • Pipeline analysis: Emerging products and technologies.
  • Annualized total RA testing market revenue by segment and market outlooks by country from 2013-2022.
  • Other key topics covered include strategic competitive assessment, market characterization, identification of unmet needs, market dynamics, and implications of the emerging technologies on the market.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline
  • Develop business strategies by understanding the trends shaping and driving the global market
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
  • Track device sales in the global market from 2012-2021
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Market Access
3.1 Rheumatoid Arthritis Testing Overview
3.2 Reimbursement Trends
3.2.1 North America
3.2.2 Europe
3.2.3 Asia-Pacific
3.2.4 South America
3.3 Mergers, Acquisitions, and Key Partnerships
4 Unmet Needs
4.1 Earlier Diagnosis
4.2 Seronegativity and Sensitivity
4.2.1 Rheumatoid Factor
4.2.2 Anti-Cyclic Citrullinated Peptide Antibody
4.2.3 14-3-3η
4.3 Novel Biomarkers for Rheumatoid Arthritis Diagnosis
5 Competitive Assessment
5.1 Company Share Analysis
5.1.1 Global
5.2 Abbott Diagnostics
5.2.1 Overview
5.2.2 Marketed Products Assessment
5.2.3 SWOT Analysis
5.3 Beckman Coulter
5.3.1 Overview
5.3.2 Marketed Products Assessment
5.3.3 Pipeline Products Assessment
5.3.4 SWOT Analysis
5.4 Bio-Rad Laboratories
5.4.1 Overview
5.4.2 Marketed Products Assessment
5.4.3 SWOT Analysis
5.5 Euro-Diagnostica
5.5.1 Overview
5.5.2 Marketed Products Assessment
5.5.3 SWOT Analysis
5.6 Inova Diagnostics
5.6.1 Overview
5.6.2 Marketed Products Assessment
5.6.3 SWOT Analysis
5.7 Quest Diagnostics
5.7.1 Overview
5.7.2 Marketed Products Assessment
5.7.3 SWOT Analysis
5.8 F. Hoffmann-La Roche
5.8.1 Overview
5.8.2 Marketed Products Assessment
5.8.3 SWOT Analysis
5.9 Siemens Healthcare
5.9.1 Overview
5.9.2 Marketed Products Assessment
5.9.3 Pipeline Products Assessment
5.9.4 SWOT Analysis
5.10 SQI Diagnostics
5.10.1 Overview
5.10.2 Marked Products Assessment
5.10.3 SWOT Analysis
5.11 Thermo Fisher Scientific
5.11.1 Overview
5.11.2 Marketed Products Assessment
5.11.3 Pipeline Products Assessment
5.11.4 SWOT Analysis
5.12 Other Companies
6 Market Outlook
6.1 Test Trends
6.1.1 Rheumatoid Factor Testing
6.1.2 Anti-Cyclic Citrullinated Peptide Antibody Testing
6.1.3 C-Reactive Protein Testing
6.2 Market Dynamics
6.2.1 Driver: Increasing Anti-CCP Antibody Testing
6.2.2 Driver: Innovative Tests for Rheumatoid Arthritis
6.2.3 Driver: Rising Demand for Lab Automation
6.2.4 Driver: Rising Prevalence of Rheumatoid Arthritis
6.2.5 Barrier: Limited Sensitivity of Existing Tests
6.2.6 Barrier: Healthcare Cost-Cutting
6.2.7 Barrier: Medical Device Excise Tax
6.3 Market Outlooks by Segment
6.3.1 Global Overview
6.3.2 Rheumatoid Factor Tests
6.3.3 Anti-Cyclic Citrullinated Peptide Antibody Tests
6.3.4 C-Reactive Protein Tests
6.4 Market Outlooks by Geography
6.4.1 Global Overview
6.4.2 US
6.4.3 France
6.4.4 Germany
6.4.5 Italy
6.4.6 Spain
6.4.7 UK
6.4.8 Japan
6.4.9 Australia
6.4.10 Brazil
6.4.11 Canada
6.4.12 China
6.4.13 India
6.4.14 Mexico
6.4.15 Russia
6.4.16 South Korea
7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Report Methodology
7.3.1 Overview
7.3.2 Coverage
7.3.3 Secondary Research
7.3.4 Forecasting Methodology
7.3.5 Primary Research - Key Opinion Leader Interviews
7.3.6 Primary Research - Physician and Industry Interviews
7.3.7 Expert Panel Validation
7.4 About the Team
7.4.1 Analysts
7.4.2 David Brady, Director of Operations - Market Research
7.4.3 Tyler Fletcher, Global Head of Medical Devices
7.5 About MediPoint
7.6 About GlobalData
7.7 Disclaimer
1.1 List of Tables
Table 1: Rheumatoid Arthritis Classification Criteria
Table 2: Medicare National Average of Clinical Laboratory Services Reimbursement for Rheumatoid Arthritis Testing, 2014-2015
Table 3: Mergers, Acquisitions, and Key Partnerships, 2014-2016
Table 4: Company Profile - Abbott Diagnostics
Table 5: Abbott Diagnostics’ RA Testing Portfolio Assessment, 2016
Table 6: SWOT Analysis - Abbott Diagnostics
Table 7: Company Profile - Beckman Coulter
Table 8: Beckman Coulter’s RA Testing Portfolio Assessment, 2016
Table 9: Beckman Coulter’s RA Testing Pipeline, 2016
Table 10: SWOT Analysis - Beckman Coulter
Table 11: Company Profile - Bio-Rad Laboratories
Table 12: Bio-Rad Laboratories’ RA Testing Portfolio Assessment, 2016
Table 13: SWOT Analysis - Bio-Rad Laboratories
Table 14: Company Profile - Euro-Diagnostica
Table 15: Euro-Diagnostica’s RA Testing Portfolio Assessment, 2016
Table 16: SWOT Analysis - Euro-Diagnostica
Table 17: Company Profile - Inova Diagnostics
Table 18: Inova Diagnostics’ RA Testing Portfolio Assessment, 2016
Table 19: SWOT Analysis - Inova Diagnostics
Table 20: Company Profile - Quest Diagnostics
Table 21: Quest Diagnostics’ RA Testing Portfolio Assessment, 2016
Table 22: SWOT Analysis - Quest Diagnostics
Table 23: Company Profile - F. Hoffmann-La Roche
Table 24: F. Hoffmann-La Roche’s RA Testing Portfolio Assessment, 2016
Table 25: SWOT Analysis - F. Hoffmann-La Roche
Table 26: Company Profile - Siemens Healthcare
Table 27: Siemens Healthcare’s RA Testing Portfolio Assessment, 2016
Table 28: Siemens Healthcare’s RA Testing Pipeline, 2016
Table 29: SWOT Analysis - Siemens Healthcare
Table 30: Company Profile - SQI Diagnostics
Table 31: SQI Diagnostics’ RA Testing Portfolio Assessment, 2016
Table 32: SWOT Analysis - SQI Diagnostics
Table 33: Company Profile - Thermo Fisher Scientific
Table 34: Thermo Fisher Scientific’s RA Testing Portfolio Assessment, 2016
Table 35: Thermo Fisher Scientific’s RA Testing Pipeline, 2016
Table 36: SWOT Analysis - Thermo Fisher Scientific
Table 37: Other Companies Involved in the Rheumatoid Arthritis Testing Market, 2016
Table 38: Global RF Test Volume Forecast (thousands) by Country, 2013-2022
Table 39: Global Anti-CCP Antibody Test Volume Forecast (thousands) by Country, 2013-2022
Table 40: Global CRP Test Volume Forecast (thousands) by Country, 2013-2022
Table 41: Global Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Table 42: RF Marker Tests Sales Forecast ($m) by Region, 2013-2022
Table 43: Anti-CCP Antibody Marker Test Sales Forecast ($m) by Region, 2013-2022
Table 44: CRP Marker Test Sales Forecast ($m) by Region, 2013-2022
Table 45: Global Rheumatoid Arthritis Testing Sales Forecast ($m) by Country, 2013-2022
Table 46: US Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Table 47: France Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Table 48: Germany Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Table 49: Italy Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Table 50: Spain Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Table 51: UK Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Table 52: Japan Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Table 53: Australia Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Table 54: Brazil Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Table 55: Canada Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Table 56: China Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Table 57: India Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Table 58: Mexico Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Table 59: Russia Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Table 60: South Korea Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Table 61: Rheumatoid Arthritis Testing - Primary Call Count by Country
1.2 List of Figures
Figure 1: Global RA Testing Market, By Company Share, 2015
Figure 2: Global RF Test Volume Forecast (thousands) by Country, 2013-2022
Figure 3: Global RF Test Volume Share Forecast (%) by Country, 2015 and 2022
Figure 4: Global Anti-CCP Antibody Test Volume Forecast (thousands) by Country, 2013-2022
Figure 5: Global Anti-CCP Antibody Test Volume Share Forecast (%) by Country, 2015 and 2022
Figure 6: Global CRP Test Volume Forecast (thousands) by Country, 2013-2022
Figure 7: Global CRP Test Volume Share Forecast (%) by Country, 2015 and 2022
Figure 8: Global Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 9: Global Rheumatoid Arthritis Analyzer Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 10: Global Rheumatoid Arthritis Manual Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 11: Global Rheumatoid Arthritis Testing Market Potential by Test, 2022
Figure 12: RF Marker Tests Sales Forecast ($m) by Region, 2013-2022
Figure 13: Anti-CCP Antibody Marker Test Sales Forecast ($m) by Region, 2013-2022
Figure 14: CRP Marker Test Sales Forecast ($m) by Region, 2013-2022
Figure 15: Global Rheumatoid Arthritis Testing Sales Forecast ($m), 2013-2022
Figure 16: Global Rheumatoid Arthritis Testing Market Share Forecast (%) by Country, 2015 and 2022
Figure 17: Global Rheumatoid Arthritis Testing Market Potential by Country, 2022
Figure 18: US Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 19: US Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 20: France Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 21: France Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 22: Germany Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 23: Germany Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 24: Italy Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 25: Italy Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 26: Spain Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 27: Spain Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 28: UK Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 29: UK Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 30: Japan Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 31: Japan Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 32: Australia Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 33: Australia Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 34: Brazil Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 35: Brazil Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 36: Canada Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 37: Canada Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 38: China Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 39: China Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 40: India Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 41: India Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 42: Mexico Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 43: Mexico Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 44: Russia Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 45: Russia Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 46: South Korea Rheumatoid Arthritis Testing Sales Forecast ($m) by Test, 2013-2022
Figure 47: South Korea Rheumatoid Arthritis Test Market Share Forecast (%) by Test, 2015 and 2022
Figure 48: Rheumatoid Arthritis Testing - Primary Call Count by Country (N=75)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook